Document is current
Any future updates will be listed below
-
Authors
Li, Wenxuan https://orcid.org/0009-0002-8792-6270
Wang, Yangang
Liu, Chuanfeng
Yu, Yongzhuo
Xu, Lili
Dong, Bingzi
- License Information
-
More Information
Article History
Received: 20 January 2025
Accepted: 4 March 2025
First Online: 24 March 2025
Declarations
:
: Wenxuan Li, Yangang Wang, Chuanfeng Liu, Yongzhuo Yu, Lili Xu, and Bingzi Dong declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
: This study was conducted in accordance with ethical standards, including approval from the Medical Ethics Committee of the Affiliated Hospital of Qingdao University (ethics approval no. QYFY WZLL 29564). Written informed consent was obtained from all participants, and data confidentiality was strictly maintained throughout the study. No participants’ personal information was disclosed or repurposed for nonresearch purposes. The authors declare no conflicts of interest regarding this study. All medications utilized in this research (chiglitazar, semaglutide, and pioglitazone) were prescribed on the basis of clinical judgment and were not provided by pharmaceutical companies for research purposes. The study was independently designed and executed without direct funding or influence from external commercial entities.
